These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 35770040)

  • 1. Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First.
    Deshpande A; Munoz J
    Ther Clin Risk Manag; 2022; 18():657-668. PubMed ID: 35770040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zanubrutinib in lymphoproliferative disorders: a comprehensive review.
    Muñoz J; Wang Y; Jain P; Wang M
    Ther Adv Hematol; 2022; 13():20406207221093980. PubMed ID: 35651781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia.
    Sarosiek S; Sermer D; Branagan AR; Treon SP; Castillo JJ
    Expert Rev Anticancer Ther; 2022 May; 22(5):471-478. PubMed ID: 35404729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
    Lim KJC; Tam CS
    Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
    [No Abstract]   [Full Text] [Related]  

  • 5. Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia.
    Muñoz J; Paludo J; Sarosiek S; Castillo JJ
    Cells; 2022 Oct; 11(20):. PubMed ID: 36291152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
    Tam CS; LeBlond V; Novotny W; Owen RG; Tedeschi A; Atwal S; Cohen A; Huang J; Buske C
    Future Oncol; 2018 Sep; 14(22):2229-2237. PubMed ID: 29869556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
    Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; Sanz RG; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyz J; Fernández de Larrea C; Belada D; Libby E; Matous JV; Motta M; Siddiqi T; Tani M; Trneny M; Minnema MC; Buske C; Leblond V; Trotman J; Chan WY; Schneider J; Ro S; Cohen A; Huang J; Dimopoulos M
    Blood; 2020 Oct; 136(18):2038-2050. PubMed ID: 32731259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BTK Inhibitors in the Frontline Management of Waldenström Macroglobulinemia.
    Varettoni M; Matous JV
    Hematol Oncol Clin North Am; 2023 Aug; 37(4):707-717. PubMed ID: 37246088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and novel BTK inhibitors in Waldenström's macroglobulinemia.
    Ntanasis-Stathopoulos I; Gavriatopoulou M; Fotiou D; Dimopoulos MA
    Ther Adv Hematol; 2021; 12():2040620721989586. PubMed ID: 33613931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
    Shadman M; Flinn IW; Levy MY; Porter RF; Burke JM; Zafar SF; Misleh J; Kingsley EC; Yimer HA; Freeman B; Rao SS; Chaudhry A; Tumula PK; Gandhi MD; Manda S; Chen DY; By K; Xu L; Liu Y; Crescenzo R; Idoine A; Zhang X; Cohen A; Huang J; Sharman JP
    Lancet Haematol; 2023 Jan; 10(1):e35-e45. PubMed ID: 36400069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
    Hillmen P; Eichhorst B; Brown JR; Lamanna N; O'Brien SM; Tam CS; Qiu L; Kazmierczak M; Zhou K; Šimkovič M; Mayer J; Gillespie-Twardy A; Shadman M; Ferrajoli A; Ganly PS; Weinkove R; Grosicki S; Mital A; Robak T; Österborg A; Yimer HA; Salmi T; Ji M; Yecies J; Idoine A; Wu K; Huang J; Jurczak W
    J Clin Oncol; 2023 Feb; 41(5):1035-1045. PubMed ID: 36395435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia.
    Tawfiq RK; Abeykoon JP; Kapoor P
    Curr Hematol Malig Rep; 2024 Jun; 19(3):120-137. PubMed ID: 38536576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial.
    Dimopoulos M; Sanz RG; Lee HP; Trneny M; Varettoni M; Opat S; D'Sa S; Owen RG; Cull G; Mulligan S; Czyz J; Castillo JJ; Motta M; Siddiqi T; Gironella Mesa M; Granell Gorrochategui M; Talaulikar D; Zinzani PL; Askari E; Grosicki S; Oriol A; Rule S; Kloczko J; Tedeschi A; Buske C; Leblond V; Trotman J; Chan WY; Michel J; Schneider J; Tan Z; Cohen A; Huang J; Tam CS
    Blood Adv; 2020 Dec; 4(23):6009-6018. PubMed ID: 33284944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia: A review.
    Moore DC
    J Oncol Pharm Pract; 2021 Dec; 27(8):1993-1999. PubMed ID: 34558376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions.
    Wolska-Washer A; Robak T
    Front Oncol; 2023; 13():1130595. PubMed ID: 37035197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström's Macroglobulinemia.
    Ababneh O; Abushukair H; Qarqash A; Syaj S; Al Hadidi S
    Clin Hematol Int; 2022 Jun; 4(1-2):21-29. PubMed ID: 35950210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib.
    Moslehi JJ; Furman RR; Tam CS; Salem JE; Flowers CR; Cohen A; Zhang M; Zhang J; Chen L; Ma H; Brown JR
    Blood Adv; 2024 May; 8(10):2478-2490. PubMed ID: 38502198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
    Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; García-Sanz R; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyż J; Fernández De Larrea C; Belada D; Libby E; Matous J; Motta M; Siddiqi T; Tani M; Trněný M; Minnema MC; Buske C; Leblond V; Treon SP; Trotman J; Wu B; Yu Y; Shen Z; Chan WY; Schneider J; Allewelt H; Cohen A; Dimopoulos MA
    Blood Adv; 2024 Apr; 8(7):1639-1650. PubMed ID: 38315878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Waldenström's macroglobulinemia - clinical symptoms and review of therapy yesterday, today and tomorrow.
    Adam Z; Pour L; Zeman D; Krejčí M; Boichuk I; Krejčí M; Štork M; Sandecká V; Král Z
    Klin Onkol; 2023; 36(3):177-191. PubMed ID: 37353346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial.
    Tedeschi A; Tam CS; Owen RG; Buske C; Leblond V; Dimopoulos M; Garcia-Sanz R; Castillo JJ; Trotman J; Treon SP; Yang K; Tang B; Allewelt H; Patel S; Chan WY; Cohen A; Chen S; Barnes G
    Future Oncol; 2024; 20(25):1789-1798. PubMed ID: 39072392
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.